The sNDA submission represents a potential catalyst for 2026, but current revenue trends are weak and the company remains in a going concern situation. Traders should monitor FDA feedback on the sNDA and any updates on commercial launch readiness.
Price Chart
Executive Summary
BioXcel Therapeutics reported declining IGALMI revenue for Q4 and full-year 2025, with net revenue down significantly year-over-year. However, the company submitted an sNDA seeking approval for IGALMI's use in the at-home treatment of agitation in bipolar and schizophrenia patients, supported by positive Phase 3 data, and is advancing commercial launch preparations. Despite reduced operating cash burn, the company continues to report substantial losses and has a negative equity position.
Key Financial Metrics
Key Facts
- IGALMI net revenue was $256,000 in Q4 2025, down from $366,000 in Q4 2024
- Full-year 2025 IGALMI revenue was $642,000, down from $2.3 million in 2024
- sNDA submitted for at-home use of IGALMI with potential FDA approval by year-end 2026
- Cash and cash equivalents totaled $28.8 million as of December 31, 2025
- Net loss for full-year 2025 was $69.9 million, wider than $59.6 million in 2024
- Total cash used in operating activities decreased to $57.6 million in 2025 from $72.0 million in 2024
Financial Impact
Revenue declined by ~72% year-over-year; operating cash use improved by $14.4 million annually
Risk Factors
- Company has identified substantial doubt about its ability to continue as a going concern
- Revenue is declining and remains minimal at $642,000 for the full year
- High net losses and negative stockholders' equity of $95.5 million
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263683 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $0.1370 | awaiting T+60 | — | — |
Aug 28, 2026 8w ago | Press Release | $0.1814 | awaiting T+60 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.7422 | awaiting T+60 | — | — |
Aug 11, 2026 10w ago | 8-K | $0.9320 | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $0.8480 | awaiting T+60 | — | — |
Jul 6, 2026 16w ago | 8-K | $1.10 | awaiting T+60 | — | — |
May 22, 2026 22w ago | Insider Cluster | $1.22 $0.8274 | ▲ +32.18% | ▲ +34.91% | — |
May 20, 2026 22w ago | 144 | $1.14 $0.8900 | ▼ −21.93% | ▼ −26.23% | — |
May 15, 2026 23w ago | 8-K | $1.14 $0.9319 | ▼ −18.25% | ▼ −22.77% | — |
May 15, 2026 23w ago | Press Release | $1.14 $0.9319 | ▲ +18.25% | ▲ +22.77% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers